Literature DB >> 25209070

Mortality and years of potential life loss in systemic lupus erythematosus: a population-based cohort study.

K Lerang1, I-M Gilboe2, D Steinar Thelle3, J T Gran4.   

Abstract

Multiple sources were used to identify 325 systemic lupus erythematosus (SLE) patients within the city of Oslo during 1999-2009 who met ≥ 4 of the American College of Rheumatology (ACR) criteria. The survival, standard mortality rate (SMR), years of potential life loss before 60 years of age (YPLL60) and causes of death of these patients were examined and compared to a matched control population. Only inception cases (127) were studied in the calculation of survival. The analysis includes underlying, immediate and contributing causes of death. The five- and 10-year survival was 95% and 90%, respectively, which was significantly reduced when compared to the general population. A total of 50 SLE patients died during the study period. Overall SMR was 3.0 (95% confidence interval (CI) 2.2-3.8) with the highest SMR found for female patients aged 16-39 years old. SLE patients had a 10 times higher rate of YPLL60 compared to the control group. YPLL emphasizes active disease and reduces the importance of cancer as a cause of death in SLE. This study demonstrates that YPLL gives additional and useful information for the prognosis of SLE, supplementing traditional methods of measuring mortality.
© The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  Systemic lupus erythematosus; epidemiology; mortality; outcome; survival rate

Mesh:

Year:  2014        PMID: 25209070     DOI: 10.1177/0961203314551083

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  33 in total

Review 1.  Pathogenic immunity in systemic lupus erythematosus and atherosclerosis: common mechanisms and possible targets for intervention.

Authors:  M Wigren; J Nilsson; M J Kaplan
Journal:  J Intern Med       Date:  2015-11       Impact factor: 8.989

2.  Cardiovascular Disease Prevention Counseling Program for Systemic Lupus Erythematosus Patients.

Authors:  Cécile M Yelnik; Monica Richey; Virginia Haiduc; Sotiria Everett; Meng Zhang; Doruk Erkan
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-06-26       Impact factor: 4.794

Review 3.  Mortality in Systemic Lupus Erythematosus: an Updated Review.

Authors:  César E Fors Nieves; Peter M Izmirly
Journal:  Curr Rheumatol Rep       Date:  2016-04       Impact factor: 4.592

4.  Survival analysis of patients with systemic lupus erythematosus in a tertiary hospital in southern Brazil.

Authors:  Jordana Vaz Hendler; Lucian de Souza; Daniele Corrêa de Freitas Zernow; Juliano Guimarães; Thiago Bertotto; Carla Forgiarini Saldanha; João Carlos Tavares Brenol; Odirlei André Monticielo
Journal:  Clin Rheumatol       Date:  2017-06-26       Impact factor: 2.980

Review 5.  Update on Lupus Nephritis.

Authors:  Salem Almaani; Alexa Meara; Brad H Rovin
Journal:  Clin J Am Soc Nephrol       Date:  2016-11-07       Impact factor: 8.237

6.  Impact of Sex on Systemic Lupus Erythematosus-Related Causes of Premature Mortality in the United States.

Authors:  Titilola Falasinnu; Yashaar Chaichian; Julia F Simard
Journal:  J Womens Health (Larchmt)       Date:  2017-09-11       Impact factor: 2.681

7.  In-hospital mortality in patients with systemic lupus erythematosus: a study from Jordan 2002-2017.

Authors:  Marwan H Adwan; Ula Qasem; Khader N Mustafa
Journal:  Rheumatol Int       Date:  2020-03-07       Impact factor: 2.631

Review 8.  Update on cardiovascular disease in lupus.

Authors:  Laura B Lewandowski; Mariana J Kaplan
Journal:  Curr Opin Rheumatol       Date:  2016-09       Impact factor: 5.006

Review 9.  CD20-Mimotope Peptide Active Immunotherapy in Systemic Lupus Erythematosus and a Reappraisal of Vaccination Strategies in Rheumatic Diseases.

Authors:  Elvira Favoino; Marcella Prete; Andrea Marzullo; Enrico Millo; Yehuda Shoenfeld; Federico Perosa
Journal:  Clin Rev Allergy Immunol       Date:  2017-04       Impact factor: 8.667

Review 10.  High-Density Lipoprotein in Lupus: Disease Biomarkers and Potential Therapeutic Strategy.

Authors:  Sang Yeop Kim; Minzhi Yu; Emily E Morin; Jukyung Kang; Mariana J Kaplan; Anna Schwendeman
Journal:  Arthritis Rheumatol       Date:  2019-11-26       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.